Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT04229849 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

164

Enrollment

OTHER_GOV

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Anrotenib plus Toripalimab
DRUG: Toripalimab

Sponsor

Henan Cancer Hospital